Seeking Alpha

The FDA accepts Sanofi's (SNY +1.85%) once-daily lixisenatide diabetes drug for review; the...

The FDA accepts Sanofi's (SNY +1.85%) once-daily lixisenatide diabetes drug for review; the company expects to launch the treatment in the EU at the end of Q1 after receiving approval earlier this month. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs